Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single...

Area of Science:

• Oncology
• Immunology
• Virology

Background:

• Oncolytic viruses and combinatorial immunotherapy are key components of cancer treatment at IOZK.
• An individualized multimodal cancer immunotherapy concept has been developed at IOZK, Cologne, Germany.

Purpose of the Study:

• To explain the scientific rationale behind a multimodal cancer immunotherapy concept.
• To present recent clinical results of this immunotherapy in glioblastoma multiforme patients.

Main Methods:

• The multimodal approach integrates oncolytic Newcastle disease virus, modulated electrohyperthermia, and a dendritic cell vaccine (IO-VAC®).
• The strategy involves systemic oncolytic virus exposure and hyperthermia to induce immunogenic cell death, followed by intradermal IO-VAC® vaccination.
• The concept extends the cancer-immunity cycle to include systemic events in the bone marrow for immune augmentation.

Main Results:

• The combination of this immunotherapy with standard treatment showed promising overall survival benefits in glioblastoma patients.
• The study highlights the role of the bone marrow as an antigen-responsive organ crucial for T cell activation and immunological memory.

Conclusions:

• Individualized multimodal immunotherapy, incorporating oncolytic viruses and dendritic cell vaccines, demonstrates potential for improving cancer treatment outcomes.
• Systemic activation of the bone marrow is recommended to augment cancer-immunity cycles and enhance therapeutic efficacy.